ArticleClinical research in cardiology : official journal of the German Cardiac Society2012
Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00469248 (Intra-Aortic Balloon Counterpulsation in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock - The Prospective, Randomised IABP SHOCK Trial for Attenuation of Multi-Organ Dysfunction Syndrome), which is not on this map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intra-Aortic Balloon Counterpulsation in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock - The Prospective, Randomised IABP SHOCK Trial for Attenuation of Multi-Organ Dysfunction Syndrome
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 123 citations in OpenAlex.
- Postmortem Immunohistochemical Findings in Early Acute Myocardial Infarction: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Impact of diabetes on outcomes of cardiogenic shock: A systematic review and meta-analysis.Diabetes & vascular disease researchPooled it
- Impact of mild therapeutic hypothermia on plasma markers of inflammation and apoptosis in non-resuscitated patients with acute myocardial infarction and cardiogenic shock.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Trial
- The effects of extracorporeal blood purification (oXiris®) in patients with cardiogenic shock who require VA-ECMO (CLEAN ECMO): a prospective, open-label, randomized controlled pilot study.Critical care (London, England) · 2025Trial
- Trial
- Temporal cytokine trajectories during microaxial flow pump support identify a high-risk inflammatory phenotype in cardiogenic shock.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Blood Count-Based Inflammatory Indices Do Not Improve Prediction of Acute Kidney Injury in Cardiogenic Shock.Journal of clinical medicine research · 2026Review
- Exploration of the Clinical Assessment and Prognostic Value of Society for Cardiovascular Angiography and Intervention Shock Staging in Patients With Acute Myocardial Infarction and Cardiogenic Shock on Veno-arterial Extracorporeal Membrane Oxygenation Support.Reviews in cardiovascular medicine · 2026Article
- Prognostic Utility of the Cytokine Profile for Predicting Major Adverse Cardiovascular Events in Acute Myocardial Infarction Following Percutaneous Coronary Intervention.International journal of general medicine · 2026Article
- Early impact of CytoSorb® adsorber on proinflammatory cytokine plasmatic levels in a porcine model of refractory cardiogenic shock supported with VA-ECMO.BMC cardiovascular disorders · 2025Article
- Interleukin-6 in Cardiogenic Shock.Current cardiology reports · 2025Review
- Function of hematopoiesis and bone marrow niche in inflammation and non-hematopoietic diseases.Life medicine · 2025Review
- Circulating levels of miR-20b-5p are associated with survival in cardiogenic shock.Journal of molecular and cellular cardiology plus · 2025Article
- CytoSorbBiomedicines · 2025Article
- Cardiometabolic shock: understanding the final turns of the downward spiral.Frontiers in cardiovascular medicine · 2025Review
- Mixed Cardiogenic-Vasodilatory Shock: Current Insights and Future Directions.JACC. Advances · 2025Review
- Risk for shock in people with acute myocardial infarction: a middle-range theory.Revista brasileira de enfermagem · 2025Article
- Cardiogenic Shock: Focus on Non-Cardiac Biomarkers.Current heart failure reports · 2024Review
- Sex-specific prediction of cardiogenic shock after acute coronary syndromes: the SEX-SHOCK score.European heart journal · 2024Article
- Cardiac Failure and Cardiogenic Shock: Insights Into Pathophysiology, Classification, and Hemodynamic Assessment.Cureus · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe IABP-SHOCK-trial was a morbidity-based randomized controlled trial in patients with infarction-related cardiogenic shock (CS), which used the change of the quantified degree of multiorgan failure as determined by APACHE II score over a 4-day period as primary outcome measure. The prospective hypothesis was that adding IABP therapy to "standard care" would improve CS-triggered multi organ dysfunction syndrome (MODS). The primary endpoint showed no difference between conventionally managed cardiogenic shock patients and those with IABP support. In an inflammatory marker substudy, we analysed the prognostic value of interleukin (IL)-1β, -6, -7, -8, and -10 in patients with acute myocardial infarction complicated by cardiogenic shock.
designInflammatory marker substudy of the prospective, randomized, controlled, open label IABP-SHOCK-trial (ClinicalTrials.gov ID-NCT00469248). SETTING AND
methodsA single-center study was performed in a 12-bed Intensive-Care-Unit in an university hospital in which 40 consecutive patients were enrolled with an observational period of 96 h.
resultsThe pro- and anti-inflammatory markers IL-6, -7, -8 and -10 showed a predictive power for mortality of infarct-related CS patients, while IL-1β did not discriminate. The maximal values during the observational period, in case of IL-7 the minimal value, showed the best power to predict mortality. Both, ROC and multivariate analyses confirmed these suggestions (area under the curve: IL-8, 0.80 ± 0.08; IL-6, 0.79 ± 0.08; IL-10, 0.76 ± 0.08; IL-7, 0.69 ± 0.08). Inflammatory markers were not affected by the presence of IABP support.
conclusionThe inflammatory response in patients with myocardial infarction complicated by cardiogenic shock, as reflected by the inflammatory markers IL-6, IL-7, IL-8 and IL-10, demonstrates a clinically relevant prognostic contribution to clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.